| Literature DB >> 31171876 |
Ryan J Sullivan1, Omid Hamid2, Rene Gonzalez3, Jeffrey R Infante4, Manish R Patel5, F Stephen Hodi6, Karl D Lewis3, Hussein A Tawbi7, Genevive Hernandez8, Matthew J Wongchenko8, YiMeng Chang8, Louise Roberts8, Marcus Ballinger8, Yibing Yan8, Edward Cha8, Patrick Hwu7.
Abstract
Melanoma treatment has progressed in the past decade with the development and approval of immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand (PD-L1) and cytotoxic T lymphocyte-associated antigen 4, as well as small molecule inhibitors of BRAF and/or MEK for the subgroup of patients with BRAFV600 mutations1-9. BRAF/MEK-targeted therapies have effects on the tumor microenvironment that support their combination with PD-1/PD-L1 inhibitors10-20. This phase Ib study (ClinicalTrials.gov, number NCT01656642 ) evaluated the safety and anti-tumor activity of combining atezolizumab (anti-PD-L1) with vemurafenib (BRAF inhibitor), or cobimetinib (MEK inhibitor) + vemurafenib, in patients with BRAFV600-mutated metastatic melanoma. Triple combination therapy with atezolizumab + cobimetinib + vemurafenib, after a 28-d run-in period with cobimetinib + vemurafenib, had substantial but manageable toxicity. Exploratory biomarker data show that the cobimetinib + vemurafenib run-in was associated with an increase in proliferating CD4+ T-helper cells but not with an increase in T-regulatory cells, as observed in the vemurafenib-only run-in period. The confirmed objective response rate was 71.8% (95% confidence interval 55.1-85.0). The estimated median duration of response was 17.4 months (95% confidence interval 10.6-25.3) with ongoing response in 39.3% of patients after 29.9 months of follow-up. Further investigation in a phase III trial is underway.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31171876 DOI: 10.1038/s41591-019-0474-7
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440